By demonstrating that heparanase is elevated in tumor cells that survive even the most intensive therapy in myeloma patients, our present study has unveiled the importance of heparanase in the outcome of anti-myeloma therapy. This evidence concerns the gene HPSE and plasma cell myeloma.